（第八届进博会）政府、专家、企业等共同努力打造攻克疾病的支持生态体系

Group 1 - The core consensus reached at the forum emphasizes the need for "good drugs," "good policies," and a "good support ecosystem" to address the challenges of Developmental Epileptic Encephalopathy (DEE) [1][2] - DEE is characterized by refractory seizures and developmental stagnation or regression in early childhood, representing a heterogeneous group of severe epilepsy syndromes [1] - The integration of multidisciplinary resources and the establishment of a standardized MDT (multidisciplinary team) model are being pursued to provide one-stop services for affected children [1] Group 2 - The forum highlighted the significant burden on families and society due to severe neurological disabilities left by DEE, calling for increased attention and support from all sectors [2] - The launch of the "Early Screening for Prostate Cancer" public awareness initiative aims to enhance public disease awareness and promote early detection [2] - PSA testing is recommended annually for men over 50 as a primary screening method for prostate cancer, which can significantly improve treatment outcomes [2][3] Group 3 - The importance of public education on early screening and diagnosis was emphasized, with expectations for the prostate cancer screening initiative to reach a broader audience [3] - AstraZeneca has been actively collaborating with various stakeholders to enhance disease awareness and screening practices [3] - Strategic partnerships among Alibaba Health, Eli Lilly, AstraZeneca, and Bayer aim to improve patient education, treatment accessibility, and digital health services [3] Group 4 - Abbott and the National Health Commission's Maternal and Child Health Center signed a memorandum to promote a fertility-friendly society and improve maternal health services [4] - Chronic respiratory diseases pose significant public health challenges in China, with ongoing efforts to advance precision treatment through a better understanding of disease mechanisms [4] - GSK is committed to introducing innovative drugs and standardizing treatment protocols in collaboration with various partners to enhance patient care [4]